Peloton Apology & Treadmill Recall | Safety Concerns

Peloton Recalls Tread+ and Tread Treadmills Following Safety Concerns
Peloton has announced its collaboration with the U.S. Consumer Product Safety Commission (CPSC), resulting in voluntary recalls for both the Tread+ and Tread versions of its at-home fitness equipment.
Refunds and Sales Halt
Customers who have acquired these treadmill systems are eligible to receive a full refund by contacting the connected fitness company. Furthermore, Peloton has consented to cease all sales and distribution of both models within the United States.
Previously, CEO John Foley expressed dissatisfaction with the CPSC’s public disclosure of its findings, deeming them inaccurate. However, today’s announcement features a markedly more apologetic statement from the executive.
CEO Apology and Commitment to Safety
“The decision to recall both products represents the appropriate course of action for the well-being of Peloton members and their families,” Foley stated. “Let me state unequivocally, Peloton erred in its initial response to the Consumer Product Safety Commission’s recall request for the Tread+. We should have proactively engaged with them from the beginning. I extend my sincere apologies for this. Today’s announcement demonstrates our understanding that collaborative work with the CPSC will enhance safety awareness among our members.”
Underlying Safety Issues and Reported Incidents
These voluntary recalls stem from persistent safety apprehensions surrounding the fitness equipment. The CPSC reports over 70 incidents, tragically including the death of a young child.
According to the commission’s report, “A six-year-old child recently suffered fatal injuries after being drawn under the rear of the treadmill. Additionally, Peloton has documented 72 instances of adults, children, pets, and objects being pulled beneath the treadmill’s rear, with 29 reports detailing injuries to children, such as severe abrasions, bone fractures, and cuts.”
CPSC Statement on the Agreement
Robert S. Adler, the acting chairman of the CPSC, conveyed in a statement, “I am gratified that the U.S. Consumer Product Safety Commission and Peloton have reached a consensus to safeguard users of the Peloton Tread+ and Tread products. The agreement, which the Commission approved this morning, mandates that Peloton immediately halt the sale and distribution of both the Tread+ and Tread in the U.S. and provide full refunds to consumers desiring to return their treadmills. This agreement between the CPSC and Peloton is the culmination of weeks of rigorous negotiation and effort, resulting in a cooperative arrangement that I believe serves the best interests of both Peloton and its consumers.”
Recall Scope and Specific Hazards
The recall encompasses approximately 125,000 Tread+ units (the original model, rebranded with the introduction of a more affordable option) and 1,050 Tread models within the U.S., alongside an additional 5,400 units in Canada.
The warning accompanying the Tread+ recall emphasizes that “Adults, children, pets, and objects can be pulled under the treadmill’s rear, creating a risk of injury or death.” The Tread’s warning notes that “The touchscreen can detach and fall, posing a potential injury hazard to consumers.”
Refund Deadline and Financial Impact
Consumers have until November 6, 2022, to claim a full refund. Following this date, the company will only offer a partial refund of an unspecified amount.
Initial Resistance and Future Outlook
Peloton’s initial reluctance was partly due to the established understanding that home fitness equipment can present safety risks, particularly in households with young children and pets. Further details regarding Peloton’s position are anticipated during tomorrow’s earnings call. The company experienced substantial growth in 2020, coinciding with the pandemic, but its shares have declined by 8% following this news. Security vulnerabilities within the platform were also publicly disclosed today.
Related Posts

LatAm Doctor Communication: Ex-Uber Eats Exec Raises $14M Seed

Chai Discovery Raises $130M Series B - AI Biotech Funding

Inito AI Antibodies: Expanding At-Home Fertility Testing

Brain Fitbit: Startup Tackles Chronic Stress with Wearable Tech

Max Hodak's New Venture: Beyond Neuralink
